Silo Pharma Secures Exclusive License for MedSpray’s Intranasal Technology for SPC-15 Drug Delivery

NERW YORK – Silo Pharma, Inc. a biopharmaceutical company at the forefront of merging traditional therapeutics with psychedelic research, announced today its new exclusive licensing agreement with Medspray Pharma BV. This agreement centers around Medspray’s innovative soft mist nasal spray technology, which has been chosen as the delivery mechanism for Silo’s SPC-15 intranasal therapeutic drug.

Eric Weisblum, CEO of Silo Pharma, detailed the company’s journey with Medspray, beginning with collaborative feasibility studies earlier this year. These studies assessed Medspray’s patented technology as a potential delivery system for SPC-15. Following promising results, Silo Pharma has decided to incorporate Medspray’s Spray Technology into its formulation. This partnership grants Silo exclusive rights to use this technology in treating a range of conditions, including post-traumatic stress disorder (PTSD), anxiety disorders, Alzheimer’s disease, and anorexia.

“We believe these rights are a valuable asset that can support Silo’s continuing research and development of novel therapeutics,” Weisblum stated, emphasizing the strategic importance of this collaboration.

Medspray’s technology stands out due to its use of silicon microchip-based spray nozzles to create a soft mist nasal spray. This approach allows for a formulation-specific, customized aerosol plume. The design is tailored to enhance deposition in the relevant regions of the nasal cavity while minimizing systemic absorption. The key advantage of this technology lies in its ability to disperse drugs efficiently from the nose to the brain, optimizing both patient safety and therapeutic effectiveness.

Silo Pharma’s adoption of Medspray’s technology represents a significant advancement in drug delivery systems, particularly for intranasal therapeutics. By optimizing the delivery mechanism, Silo aims to improve the efficacy and safety of treatments for a variety of complex disorders. This partnership is a notable example of the growing trend in the pharmaceutical industry to integrate cutting-edge technology into drug development and delivery, potentially opening new avenues for treatment and research in the field of mental health and neurodegenerative diseases.